title: A novel anti-CD19 monoclonal antibody (GBR 401) with high killing activity against B cell malignancies.
abstract: BACKGROUND
  CD19 is a B cell lineage specific surface receptor whose broad expression, from pro-B cells to early plasma cells, makes it an attractive target for the immunotherapy of B cell malignancies. In this study we present the generation of a novel humanized anti-CD19 monoclonal antibody (mAb), GBR 401, and investigate its therapeutic potential on human B cell malignancies.
  
  
  METHODS
  GBR 401 was partially defucosylated in order to enhance its cytotoxic function. We analyzed the in vitro depleting effects of GBR 401 against B cell lines and primary malignant B cells from patients in the presence or in absence of purified NK cells isolated from healthy donors. In vivo, the antibody dependent cellular cytotoxicity (ADCC) efficacy of GBR 401 was assessed in a B cell depletion model consisting of SCID mice injected with healthy human donor PBMC, and a malignant B cell depletion model where SCID mice are xenografted with both primary human B-CLL tumors and heterologous human NK cells. Furthermore, the anti-tumor activity of GBR 401 was also evaluated in a xenochimeric mouse model of human Burkitt lymphoma using mice xenografted intravenously with Raji cells. Pharmacological inhibition tests were used to characterize the mechanism of the cell death induced by GBR 401.
  
  
  RESULTS
  GBR 401 exerts a potent in vitro and in vivo cytotoxic activity against primary samples from patients representing various B-cell malignancies. GBR 401 elicits a markedly higher level of ADCC on primary malignant B cells when compared to fucosylated similar mAb and to Rituximab, the current anti-CD20 mAb standard immunotherapeutic treatment for B cell malignancies, showing killing at 500 times lower concentrations. Of interest, GBR 401 also exhibits a potent direct killing effect in different malignant B cell lines that involves homotypic aggregation mediated by actin relocalization.
  
  
  CONCLUSIONS
  These results contribute to consolidate clinical interest in developing GBR 401 for treatment of hematopoietic B cell malignancies, particularly for patients refractory to anti-CD20 mAb therapies.
authors.forename: Caroline S
authors.initials: CS
authors.lastname: Breton
authors.forename: Aimable
authors.initials: A
authors.lastname: Nahimana
authors.forename: Dominique
authors.initials: D
authors.lastname: Aubry
authors.forename: Julie
authors.initials: J
authors.lastname: Macoin
authors.forename: Pierre
authors.initials: P
authors.lastname: Moretti
authors.forename: Martin
authors.initials: M
authors.lastname: Bertschinger
authors.forename: Samuel
authors.initials: S
authors.lastname: Hou
authors.affiliation: Service and Central Laboratory of Hematology, University Hospital of Lausanne, Rue du Bugnon 46, 1011- CHUV, Lausanne, Switzerland. michel.duchosal@chuv.ch.
authors.forename: Michel A
authors.initials: MA
authors.lastname: Duchosal
authors.forename: Jonathan
authors.initials: J
authors.lastname: Back
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000494:pharmacology*; D018941:Antigens, CD19 / Q000276:immunology*; D002051:Burkitt Lymphoma / Q000188:drug therapy*; D045744:Cell Line, Tumor; D006801:Humans; D051379:Mice; D016513:Mice, SCID; D023041:Xenograft Model Antitumor Assays
chemical_list: D000911:Antibodies, Monoclonal; D018941:Antigens, CD19
references.citation: Proc Natl Acad Sci U S A. 2011 Aug 2;108(31):12669-74
references.pmid: 21768335
references.citation: Ann Hematol. 2004 Apr;83(4):201-5
references.pmid: 14648023
references.citation: Leuk Res. 2008 Apr;32(4):625-32
references.pmid: 17706771
references.citation: J Immunol. 2006 Nov 15;177(10):7435-43
references.pmid: 17082663
references.citation: Semin Oncol. 2006 Apr;33(2 Suppl 5):S2-14
references.pmid: 16720198
references.citation: J Clin Invest. 2009 Aug;119(8):2143-59
references.pmid: 19620786
references.citation: Clin Cancer Res. 1999 Mar;5(3):611-5
references.pmid: 10100713
references.citation: Oncogene. 2004 Jul 22;23(33):5664-74
references.pmid: 15184883
references.citation: Blood. 2011 Apr 28;117(17):4530-41
references.pmid: 21228331
references.citation: Blood. 1984 Jun;63(6):1424-33
references.pmid: 6609729
references.citation: MAbs. 2012 May-Jun;4(3):326-40
references.pmid: 22531441
references.citation: J Immunol. 1995 Apr 1;154(7):3096-104
references.pmid: 7534787
references.citation: BMC Cancer. 2009 Feb 18;9:58
references.pmid: 19226457
references.citation: J Immunol. 2004 Mar 1;172(5):3280-8
references.pmid: 14978136
references.citation: Nat Rev Mol Cell Biol. 2007 Nov;8(11):931-7
references.pmid: 17712358
references.citation: Diagn Pathol. 2011 Apr 12;6:33
references.pmid: 21486448
references.citation: Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):5810-2
references.pmid: 14676100
references.citation: Leuk Lymphoma. 2013 Nov;54(11):2500-5
references.pmid: 23452151
references.citation: Cancer Res. 2003 Sep 1;63(17):5480-9
references.pmid: 14500384
references.citation: Leukemia. 2013 Jun;27(6):1263-74
references.pmid: 23307031
references.citation: Blood. 2010 Mar 25;115(12):2420-9
references.pmid: 20089966
references.citation: Cancer Immunol Immunother. 2010 Feb;59(2):257-65
references.pmid: 19657637
references.citation: Springer Semin Immunopathol. 2006 Dec;28(4):351-64
references.pmid: 17091246
references.citation: J Clin Oncol. 2011 Feb 10;29(5):532-43
references.pmid: 21220592
references.citation: J Mol Biol. 2004 Mar 5;336(5):1239-49
references.pmid: 15037082
references.citation: Hematology Am Soc Hematol Educ Program. 2011;2011:243-9
references.pmid: 22160041
references.citation: Drugs. 2007;67(3):333-50
references.pmid: 17335294
references.citation: J Pharmacol Exp Ther. 2010 Oct;335(1):213-22
references.pmid: 20605905
references.citation: Cancer Res. 2008 Oct 1;68(19):8049-57
references.pmid: 18829563
references.citation: Br J Haematol. 2011 Nov;155(4):426-37
references.pmid: 21902688
references.citation: Mol Immunol. 2012 Mar;50(3):134-41
references.pmid: 22305040
references.citation: Leuk Lymphoma. 1995 Aug;18(5-6):385-97
references.pmid: 8528044
references.citation: Oncogene. 2003 Oct 20;22(47):7359-68
references.pmid: 14576843
references.citation: Genes Cells. 2011 Nov;16(11):1071-80
references.pmid: 22023369
references.citation: Drug Des Devel Ther. 2009 Sep 21;3:7-16
references.pmid: 19920917
references.citation: PLoS One. 2012;7(8):e42426
references.pmid: 22879978
references.citation: Proc Natl Acad Sci U S A. 2005 Oct 18;102(42):15178-83
references.pmid: 16217038
references.citation: Blood. 2010 Jun 24;115(25):5191-201
references.pmid: 20223920
references.citation: Blood. 2009 Apr 16;113(16):3735-43
references.pmid: 19109559
references.citation: Haematologica. 2011 Dec;96(12):1822-30
references.pmid: 21880632
references.citation: J Clin Pathol. 1998 May;51(5):364-9
references.pmid: 9708202
references.citation: Blood. 2011 Nov 10;118(19):5178-88
references.pmid: 21948297
references.citation: J Allergy Clin Immunol. 2008 Jan;121(1):13-21; quiz 22-3
references.pmid: 18206502
references.citation: N Engl J Med. 2012 May 24;366(21):2008-16
references.pmid: 22621628
references.citation: Blood. 2012 Apr 12;119(15):3523-33
references.pmid: 22354003
references.citation: Apoptosis. 2006 Jun;11(6):1013-23
references.pmid: 16544097
references.citation: Haematologica. 2009 Apr;94(4):507-17
references.pmid: 19278964
references.citation: Blood. 2011 Apr 28;117(17):4519-29
references.pmid: 21378274
references.citation: Hematology Am Soc Hematol Educ Program. 2007;:233-42
references.pmid: 18024635